Laith Haddad

Dr. Laith Haddad

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2023 in Pediatric Neurology
Verified
Journal Article
Closed access
LHLaith Haddad
Laith Haddad
KPKailash Pawar
Kailash Pawar
CPCarina H. Perdew
Carina H. Perdew
GDGrace Dunker
Grace Dunker
SBSaru Bansal
Saru Bansal
LBLalit Bansal
Lalit Bansal

Verified
Journal Article
Open access
PDF file
DCDaniel Charouf
Daniel Charouf
Derryl Joseph MillerDerryl Joseph Miller
Derryl Joseph Miller
LHLaith Haddad
Laith Haddad
FWFletcher White
Fletcher White
RBRose-Mary Boustany
Rose-Mary Boustany
MOMakram Obeid
Makram Obeid
Advances in genetics led to the identification of hundreds of epilepsy-related genes, some of which are treatable with etiology-specific interventions. However, the diagnostic yield of next-generation sequencing (NGS) in unexplained epilepsy is highly variable (10–50%). We sought to determine the diagnostic yield and clinical utility of NGS in children with unexplained epilepsy that is accompanied by neurodevelopmental delays and/or is medically intractable. A 5-year retrospective review was conducted at the American University of Beirut Medical Center to identify children who underwent whole exome sequencing (WES) or whole genome sequencing (WGS). Data on patient demographics, neurodevelopment, seizures, and treatments were collected. Forty-nine children underwent NGS with an overall diagnostic rate of 68.9% (27/38 for WES, and 4/7 for WGS). Most children (42) had neurodevelopmental delays with (18) or without (24) refractory epilepsy, and only three had refractory epilepsy without delays. The diagnostic yield was 77.8% in consanguineous families (18), and 61.5% in non-consanguineous families (26); consanguinity information was not available for one family. Genetic test results led to anti-seizure medication optimization or dietary therapies in six children, with subsequent improvements in seizure control and neurodevelopmental trajectories. Not only is the diagnostic rate of NGS high in children with unexplained epilepsy and neurodevelopmental delays, but also genetic testing in this population may often lead to potentially life-altering interventions.

1 April 2021 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Closed access
FJFatima Jaafar
Fatima Jaafar
LHLaith Haddad
Laith Haddad
DHDima Habanjar
Dima Habanjar
LCLama Charafeddine
Lama Charafeddine
KYKhalid Yunis
Khalid Yunis
MOMakram Obeid
Makram Obeid

6 June 2026 in BMC Neurology
Verified
Journal Article
Open access
ABAmani A. Bannout
Amani A. Bannout
FHFatima H. Hussein
Fatima H. Hussein
LHLaith Haddad
Laith Haddad
Bell's palsy (idiopathic peripheral facial nerve paralysis) is uncommon in children and is particularly rare in infants younger than one year of age. Its occurrence following viral infections, including coronavirus disease 2019 (COVID-19), is exceedingly rare. We report a case of Bell's palsy in an infant following COVID-19 infection and provide a review of the relevant pediatric literature. We report the case of a 2-month-old female infant who developed left-sided facial weakness shortly after a COVID-19 infection. She had previously been healthy, except for a COVID-19-positive upper respiratory infection at the age of 4 weeks. Three weeks after her infection resolved, her parents noticed the sudden onset of left facial drooping, which progressed over the following three days. A diagnosis of peripheral facial nerve palsy following COVID-19 infection was proposed. Given the absence of clear treatment guidelines for infants, management options were carefully considered. The patient was ultimately started on oral prednisolone in addition to protective eye care. She demonstrated gradual clinical improvement during treatment, and at follow-up several weeks later, complete recovery of normal facial movement was observed. This case highlights that Bell's palsy, although extremely rare in infancy, may occur following a viral infection such as COVID-19. A prompt and thorough evaluation is essential to exclude alternative causes of facial paralysis. Despite no clear guidelines or recommendations favoring corticosteroid treatment vs conservative management in this age category, a decision of pharmacologic treatment was taken. In this case, corticosteroid treatment was well tolerated, and no adverse events were observed. Further studies are needed to evaluate the correlation between COVID-19 infection and facial palsy in infants, and to further assess the efficacy and safety of oral prednisolone in this age group.